{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This cohort study was a single-arm phase 2 trial"
      },
      "Participants": {
        "score": 1,
        "evidence": "patients with high-risk, pMMR rectal cancer"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants received 3 cycles of induction oxaliplatin and capecitabine combined with camrelizumab and radiotherapy (50.6 Gy in 22 fractions) with concurrent capecitabine."
      },
      "Objective": {
        "score": 1,
        "evidence": "To evaluate the safety and efficacy of TNT with induction chemoimmunotherapy followed by long-course chemoradiation in patients with high-risk, pMMR rectal cancer"
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary end point was pathologic complete response rate."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Of 25 patients enrolled"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "22 patients (88%) completed the TNT schedule."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The pathologic complete response rate was 33.3% (7/21)."
      },
      "Harms": {
        "score": 1,
        "evidence": "The most common adverse event was nausea (80%, 20/25); grade 3 toxic effects occurred in 9 of 25 patients (36%)."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 11,
    "max_score": 25
  },
  "model": "gpt-4o"
}